Search Results
Jun 01, 2026, 10:00 ET Jeep® Brand and Marvel Reveal Next Phase of Collaboration in New 'The Original Superheroes' Summer of Jeep Campaign
white and blue to mark the July 4 celebration.The Jeep brand's "The Original Superheroes" and "Origin Story," both directed by Anthony Leonardi III, are produced in partnership with Chicago-based advertising agency Highdive.Marvel Marvel is one of the world's most prominent
More news about: Stellantis
Jun 01, 2026, 09:57 ET Financial Literacy in America Has Declined to Its Lowest Level in a Decade, New TIAA Institute-GFLEC Report Finds
all of TIAA's annuity products.iii. As of March 31, 2026, assets under management across
More news about: TIAA Institute
Jun 01, 2026, 09:08 ET Whirlpool Announces Offering of Secured Notes
depositing with the trustee under the Existing Notes Indenture funds sufficient to pay the principal of and interest on such Existing Notes as and when due, (iii) repay the amount outstanding under the Company's existing unsecured revolving credit facility, and (iv) pay fees and expenses in connection with the
More news about: Whirlpool Corporation
Jun 01, 2026, 09:00 ET BRUICHLADDICH CELEBRATES 25 YEARS WITH THE RETURN OF YELLOW SUBMARINE III
New limited edition Bruichladdich Yellow Submarine III is the second special release celebrating 25 years since Bruichladdich's resurrectionThird outing for one of the distillery's most beloved cult bottlings from the tongue in cheek Whisky of Mass Distinction seriesUnpeated
More news about: Bruichladdich
Jun 01, 2026, 09:00 ET PEOPLE INCORPORATED PROPOSES TO ACQUIRE MGM RESORTS INTERNATIONAL FOR $48.30 PER SHARE IN CASH
policies, economics or features (including those implemented by Google), as well as the potential expiration or modification of key commercial agreements, (iii) our ability to effectively market our products and services in a cost-efficient manner across evolving digital channels, (iv) our dependence on advertising
More news about: People Incorporated
Jun 01, 2026, 08:49 ET Patient First Coalition Supports DEA's Medical Cannabis Review Process Providing Experts Advocating for Schedule III Transition Moritorium - Supporting Medical
Drug Enforcement Administration's review and public hearing process regarding the proposed transition of medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. Calling for a moritorium to allow appropriate medical transition. As part of this national effort, the Patient
More news about: Patient First Coalition
Jun 01, 2026, 08:31 ET The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
antibodyAkeso's ivonescimab (AK112, SMT112) is a first-in-class PD-1/VEGF bispecific antibody and the first candidate in this category to advance into Phase III clinical trials. Developed using the company's proprietary Tetrabody platform, the therapy is designed to simultaneously inhibit PD-1 interactions with
More news about: DelveInsight Business Research, LLP
Jun 01, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.42 Million Tokens, and Total Crypto and Total Cash Holdings of $11.6 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH
More news about: Bitmine Immersion Technologies, Inc.
Jun 01, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.42 Million Tokens, and Total Crypto and Total Cash Holdings of $11.6 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
Jun 01, 2026, 08:18 ET North Boulder Dental Welcomes Boulder Native Adam Belford, DDS
with his wife, Maddison, and their two daughters, Elsie and Lily."We are thrilled to welcome Dr. Belford to our practice," said Paul A. Sica III, DMD, of North Boulder Dental. "His commitment to patient-centered care and strong clinical background make him a wonderful addition to our team and
More news about: North Boulder Dental
Jun 01, 2026, 08:00 ET MillerKnoll Announces Leadership Transition
senior leadership positions at MillerKnoll and brings extensive knowledge and insights from his more than 25 years in the industry," said John R. Hoke III, Chairman of the Board. "The Board appreciates Jeff stepping into the CEO role on an interim basis, and we are confident that MillerKnoll is well positioned
More news about: MillerKnoll
Jun 01, 2026, 07:00 ET Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
investigational use: The use of LYMPHIR in this study was investigational and outside of its FDA-approved indication of relapsed or refractory Stage I–III cutaneous T-cell lymphoma. LYMPHIR is not approved by the FDA for the treatment of gynecologic malignancies or any solid tumor, and the safety and efficacy
More news about: Citius Oncology, Inc.
Jun 01, 2026, 07:00 ET Summit Midstream Corporation Announces Inaugural $35 Million Stock Repurchase Program
shale formations in North Dakota; (ii) the Denver-Julesburg Basin, which includes the Niobrara and Codell shale formations in Colorado and Wyoming; (iii) the Fort Worth Basin, which includes the Barnett Shale formation in Texas; (iv) the Arkoma Basin, which includes the Woodford and Caney shale formations
More news about: Summit Midstream Corporation
Jun 01, 2026, 07:00 ET Thesis Gold & Silver Strengthens Team with Appointment of Dimitry Demianyuk as EVP Project Development
unlock the full value of the project."Thesis granted (i) 250,000 stock options (the "Options"); (ii) 53,500 restricted share units ("RSUs"); and (iii) 53,500 performance share units ("PSUs") to an officer, with all awards governed by the Company's Omnibus Long-Term Incentive Plan and each applicable
More news about: Thesis Gold & Silver Inc.
Jun 01, 2026, 07:00 ET Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through
More news about: Decoy Therapeutics, Inc
Jun 01, 2026, 06:30 ET Trilogy Metals Provides Update on U.S. Department of War Strategic Equity Investment and Extends Closing Deadline to July 31, 2026
Government approved the Ambler Access Project and authorized a potential US$35.6 million strategic equity investment in Trilogy Metals pursuant to Title III of the Defense Production Act, administered by the U.S. Department of War. The investment will be structured in part as a direct equity placement in
More news about: Trilogy Metals Inc.
Jun 01, 2026, 06:19 ET Kenon Holdings Reports Q1 2026 Results and Additional Updates
increase in revenue from generation and sale of electricity of $84 million, (ii) an increase of revenue from capacity payments of $14 million, offset by (iii) realization of derivatives for hedging electricity prices of $30 million; andRevenue from sale of electricity (retail) activities in the
More news about: Kenon Holdings Ltd.
Jun 01, 2026, 06:01 ET A combined therapeutic strategy aims to improve disease control in advanced hormone‑sensitive prostate cancer
congress. On the one hand, the company presented, in collaboration with the Menarini Group, the design of the ADELA study, an international phase III trial evaluating the selective estrogen receptor degrader (SERD) elacestrant combined with everolimus versus elacestrant monotherapy. The study includes
More news about: MEDSIR
Jun 01, 2026, 05:00 ET CerraCap Impact Venture Capital Appoints Former Silicon Valley Bank and Equifax CIO Mark Rohrwasser to Lead CXO Council
with practical insight, strategic guidance, and enterprise connectivity."The CXO Council will play a critical role in supporting CIVC's Fund III and Fund IV investment activities by providing seasoned operator perspectives during investment diligence and helping identify emerging technology trends,
More news about: CerraCap Impact Venture Capital
Jun 01, 2026, 03:04 ET China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
clearance to conduct clinical trials in 2021, Cipepofol was granted a waiver for Phase II trials in the United States and advanced directly to pivotal Phase III trials. All clinical studies were completed in 2024, yielding superior results in a head-to-head comparison against the standard of care. In July 2025,
More news about: Haisco
Jun 01, 2026, 01:51 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
bladder cancer, including those with renal dysfunction.Supportive Cancer Care: Additional Evidence for New Antiemetic DrugThe Phase III PROTECT study, led by Professor Li Zhang and Professor Yuhong Li of the Sun Yat-sen University Cancer Center, demonstrated that Fosrolapitant and Palonosetron
More news about: Hengrui Pharma
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
therapies.Minghui's lead assets include an innovative topical JAK inhibitor currently under NDA review in China; a subcutaneous IGF-1R antibody in Phase III trials for thyroid eye disease; a novel PD-1/VEGF bispecific antibody in Phase 2 trials, being evaluated in combination with a TROP2 ADC; and a B7-H3
More news about: Minghui Pharmaceutical
May 31, 2026, 23:51 ET Aphranel® MagiCCrystal CaHA Filler obtient la certification MDR de l'UE en tant qu'injectable régénérateur de première qualité
duré deux ans et sept mois dans le cadre de la procédure prévue par le règlement MDR pour les dispositifs médicaux implantables résorbables de classe III à haut risque, sans recours à des voies d'équivalence ni à des dérogations.Pour obtenir la certification, Moyom Biotechnology a suivi le processus
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel
May 31, 2026, 23:50 ET Aphranel® MagiCCrystal CaHA Filler erhält die EU MDR-Zertifizierung als hochwertiges regeneratives Injektionsmittel
31. Dezember 2027 nicht mehr auf dem EU-Markt verbleiben.Das Zertifizierungsverfahren dauerte 2 Jahre und 7 Monate im Rahmen des MDR-Pfads der Klasse III für resorbierbare implantierbare Medizinprodukte mit hohem Risiko, ohne Gleichwertigkeitsstrecken oder Ausnahmen.Zur Unterstützung der Zertifizierung
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
NSCLC.Next Step – Phase III Registrational MRCT Planned by Year-EndThe ongoing global Phase I/II trial has enrolled nearly 300 patients across China and Australia, with U.S. Investigational New Drug (IND) clearance now obtained. CStone plans to initiate the first Phase III global multi‑regional
More news about: CStone Pharmaceuticals